Q1 2025 BioRestorative Therapies Inc Earnings Call Transcript
Key Points
- BioRestorative Therapies Inc (BRTX) achieved FDA fast track designation for their BRTX-100 program, facilitating development and review processes.
- The company reported no serious adverse events in their ongoing Phase II study for BRTX-100, indicating a positive safety profile.
- Preliminary data from the BRTX-100 trial shows promising trends in pain reduction and functional improvement.
- BioRestorative Therapies Inc (BRTX) ended the quarter with a strong financial position, holding $9.1 million in cash, cash equivalents, and marketable securities with no outstanding debt.
- The company has expanded its intellectual property portfolio, enhancing protection for its ThermoStem program targeting obesity and metabolic disorders.
- BioRestorative Therapies Inc (BRTX) reported a decrease in quarterly revenues from $35,000 in Q1 2024 to $25,000 in Q1 2025.
- The company's net loss increased significantly to $5.3 million in Q1 2025 from $2.2 million in Q1 2024.
- Enrollment challenges persist due to strict criteria for the BRTX-100 trial, although new recruitment strategies are being implemented.
- There is uncertainty regarding the potential interim analysis of the BRTX-100 trial, which could impact the trial's progression.
- The company is still in discussions for a potential license agreement for its ThermoStem program, with no assurance of reaching a mutually acceptable agreement.
Good afternoon, everyone, and welcome to the BioRestorative Therapies first-quarter 2025 investor call. (Operator Instructions) Please note, this conference is being recorded.
I will now turn the conference over to your host, Stephen Kilmer, Investor Relations. Stephen, the floor is yours.
Thank you, Jenny. Good afternoon, everyone. Let me start by pointing out that this conference call will include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All forward-looking statements are based on BioRestorative Therapies' current beliefs, assumptions, and expectations, and such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. No forward-looking statement can be guaranteed.
For details on factors, among others, that could affect expectations, see Part 1 Item 1A of our annual
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
